Effective immunotherapy for type 1 diabetes (T1D) relies on active induction of peripheral tolerance. Myeloid-derived suppressor cells (MDSCs) play a critical role in suppressing immune responses in various pathologic settings via multiple mechanisms, including expansion of regulatory T cells (Tregs). In this study, we investigated whether MDSCs could act as APCs to induce expansion of Ag-specific Tregs, suppress T cell proliferation, and prevent autoimmune T1D development. We found that MDSCmediated expansion of Tregs and T cell suppression required MHC-dependent Ag presentation. A murine T1D model was established in INS-HAIRAG _,_ mice in which animals received CD4-HA-TCR transgenic T cells via adoptive transfer. We found a significant reduction in the incidence of diabetes in recipients receiving MDSC plus HA, but not OVA peptide, leading to 75% diabetes-free mice among the treated animals. To test further whether MDSCs could prevent diabetes onset in NOD mice, nondiabetic NOD/SCID mice were injected with inflammatory T cells from diabetic NOD mice. MDSCs significantly prevented diabetes onset, and 60% of MDSC-treated mice remained diabetes free. The pancreata of treated mice showed significantly lower levels of lymphocyte infiltration in islet and less insulitis compared with that of the control groups. The protective effects of MDSCs might be mediated by inducing anergy in autoreactive T cells and the development of CD4+CD25+Foxp3+ Tregs. Thist study demonstrates a remarkable capacity of transferred MDSCs to downregulate Ag-specific autoimmune responses and prevent diabetes onset, suggesting that MDSCs possess great potential as a novel cell-based tolerogenic therapy in the control of TID and other autoimmune diseases.
T ype I diabetes (TID; diabetes mellitus) is an insulindependent disorder characterized by kidney failure, blindness, heart disease, and chronic ulcers (I). It is now clear that the chronic inflammatory· response against specific autoantigens, mainly insulin, leads to the eventual destruction of insulin-producing endocrine (3 cells. Daily injection of insulin cannot match the naturally precise timing and dosing of insulin secretion of the pancreas in response to hyperglycemia. Even well-managed diabetic patients, therefore, can experience severe treatment side effects and worsening of their disease (2) . More recently, a variety of strategies has been developed, aimed at reestablishing physiological insulin production in diabetic patients (3) . Despite these advancements, devising a means capable of restoring self-tolerance or specifically down-modulating autoimmunity remains a critical step toward preventing and/or reversing TID. In this respect, regulatory T cells (Tregs) have received particular attention (4) .
Myeloid-derived suppressor cells (MDSCs) represent a population of myeloid origin with immunoregulatory activity. These cells can function to suppress Ag-specific and nonspecific T cell responses via diverse mechanisms (5) (6) (7) (8) (9) . Accumulating evidence has implicated a potential broad application of MDSCs as a novel cell-based immunotherapy within the tields of transplantation and autoimmune diseases (10) (11) (12) . To date, transfer of MDSCs has been shown to be capable of inducing immune tolerance in allogeneic bone marrow transplantation ( 13) , prolonging the survival of allo-skin transplants via inhibitory receptor lg-like transcript 2 mediated tolerance (14) , participating in anti-CD28-mediated tolerance in allo-kidney transplantation ( 15) , and amelioration of symptoms in the inflammatory bowel disease model (10) . In this study, we have shown that adoptive transfer of CD115+Gr-1+ MDSCs plus hemagglutinin (HA) peptides efficiently prevents the onset of HA-specitic TCR T cell-induced diabetes in INS-HA/RAG_,_ recipient mice. Further, MDSCs prevented diabetes onset in NOD/SCID mice and maintained these mice diabetes-free for the long term. 
Materials and Methods

SPONSOR/MONITOR'S REPORT NUMBER(S)
The Jackson Laboratory (Bar Harbor, ME). All animal experiments were performed in accordance with the animal guidelines of the Mount Sinai School of Medicine.
Peptide and Abs
HA peptide e 10 SFERFEIFPKE 120 ) and OVA peptide e 23 1SQAVHAA-HAEINEAGR339) were purchased from Washington Biotechnology (Baltimore, MD). All Huorescence-conjugated monoclonal Abs were purchased from eBioscience (San Diego, CA).
Isolation of MDSCs
BALB/c mice bearing syngeneic colon cancer MCA26 and C57BL6 mice bearing syngeneic Lewis lung carcinoma were used as the source of MDSCs. The detailed Percoll protocol for MDSC isolation has been described previously (6) . The fraction n Gr-t•cDJI5+ MDSCs were sorted by flow cytometry, and cells with a purity of98% were used in the INS-HA diabetic model.
Treg expansion and suppression of CD4+ CD25-T cell proliferation by MDSCs
CFSE-Iabeled, purified CD4.CD25+ Tregs and CD4.CD25-T cells from naive CD4-HA-TCR transgenic mice (BALB/c background) or CD4 OVAspecific TCR transgenic (OT-11) mice (B6 background) were cocultured with MDSCs, at a 4: I ratio, in the presence of HA or OVA peptides (0.5 J.Lg/ml) and IL-2 (I 00 U/ml) for 4 d. Proliferation was assessed by flow cytometry (CFSE dilution) using fluorochrome-labeled Abs against CD4, CD25. and Foxp3 or isotype controls. Mouse glucose levels were meac;ured daily using a blood glucose meter (Bayer, Pittsburgh, PA) to determine the onset of diabetes. Mice were considered diabetic when their blood glucose level was <==200 mg/dl for two consecutive measurements. Soned MDSCs (5 x 10 6 ceiVmouse) were transferred twice, on the first and founh days after T cell transfer.
Diabetes model
NOD/SCID diabetic model
CD4+ T cells were purified from the spleens of diabetic NOD females using a CD4 isolation kit. To generate MDSCs, mouse mammary tumor TS/A cells ( 10 6 ) were implanted into the fat pad of NOD/SCID mice. Two to three weeks later, MDSCs (CDIJb•Gr-1• cells) were positively selected from bone marrow using Ab-conjugated Miltenyi beads (Miltenyi, Auburn, CA). Female NOD/SCID mice aged 6 wk received a tail vein injection of PBS, CD4+ T cells from diabetic NOD mice (2 x 10\ and control CD4+ T cells from normal mice flus a single various dose response of MDSCs (0, or0.5, or I, or 2 x 10 ).
Using an Elite glucometer (Bayer), fasting blood glucose concentrations were measured daily staning postinjection (days 0 to 100). Mice with fasting blood glucose concentrations over 200 mg/dl for two consecutive measurements were considered diabetic. To determine the severity of insulitis, pancreata were examined by H&E staining. At least 10 islets per pancreas were examined to assess the degree of insulitis. The severity of insulitis was scored as follows: 0, normal; I. leukocyte infiltration around islets; 2, <50% leukocyte infiltration; and 3, >50% leukocyte infiltration using published criteria ( 16) .
Histopathological analysis
Pancreatic tissue wao; fixed in 10% buffered formalin solution and embedded in paraffin. Prepared sections were stained by Mayer's H&E. For each organ, 10 sections were analyzed. Staining for intracellular insulin was performed using polyclonal rabbit anti-insulin (Santa Cruz Biotechnology, Santa Cruz, CA) in conjunction with HRP-goat-anti-rabbit conjugate (Southern Biotechnologies, Birmingham, AL). Additional tissue samples were frozen at -8o·c. and frozen sections were cut in stepwise fashion (8 J.Lm per section). Staining for CD4 T cells in islets was performed using monoclonal anti-CD4 (eBioscience) in conjunction with HRP-goat-amimouse conjugate (Southern Biotechnologies).
Cytokine detection by EUSA
The concentrations of mouse IFN--y, IL-10, and TGF-~ in the culture supernatants were meac;ured by ELISA (R&D Systems).
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Suppression/proliferation assay
Column-enriched Thy-1 + T cells (I X I 0 5 ) from TCR transgenic mice or treated mice were cocultured with HA peptide (5 J,Lg/ml) alone or in the presence of escalating numbers of CD2.'i+ T cells recovered from treated nondiabetic mice in 96-well microplates. Irradiated (2500 rad) naive splenocytes (5 X 10 4 ) were used as APCs. ('H]Thymidine was added during the last 8 h of 72 h culture.
Quantitative real-time PCR
Total RNA was extracted using TRizol reagent (Invitrogen). The reverse transcription-PeR (RT-PCR) procedure (One-step RT-PCR kit; Qiagen, Valencia, CA) using primers for Foxp3 and for GAPDH (internal control) has been previously described (9) . For quantitative real-time PCR, reversetranscribed eDNA was amplified by real-time PCR with SYBR Green Universal PCR Mac;termix (Bio-Rad, Richmond. CA). Samples were analyzed in duplicate with the JQ-Cycler (Bio-Rad). The normalized signal level was calculated based on the ratio to the corresponding GAPDH signal.
Results
MDSCs can act as APCs for Treg expansion and suppress effector T cell proliferation in vitro
Our laboratory and others have found that MDSCs from tumorbearing mice can suppress T cell proliferation and induce Treg expansion (5-8, 9, 17}. We have reponed that MDSC-mediated Treg activation requires the presence of IFN-'Y and IL-10 (6). We then studied whether MDSCs can act as APCs to mediate Treg activation and, therefore, lead to the development of a better strategy for cell-based tolerogenic therapy using MDSCs.
To determine whether MDSC-mediated Treg expansion was Ag-dependent and MHC-restricted, CD4.CD25+ splenic T cells purified from naive OT-11 mice were labeled with CFSE and cocultured with wild-type (WT) MDSCs or MHC class I or II KO MDSCs in the presence or absence of OVA peptides, or with MDSCs isolated from tumor-bearing, constitutive actin promoterdriven, OVA-expressing, transgenic mice. Based on FACS analysis for the presence of CFSE-labeled cells ( 4.5%) or OVA peptide alone (46.1 :!: 4.7%) ( Fig. 18 ; t test, p < 0.001 ). Treg expansion was similarly mediated by actin-OVAexpressing MDSCs (67.4 :!: 2.1 %; p < 0.00 1), which contain endogenous OVA. Furthermore, Treg expansion in the presence of MHC class II KO MDSCs and OVA peptide (46.9 ± 6.9%) was significantly decreased to levels similar to those observed when cultured in the presence of OVA peptide alone. However, even when cultured with MHC class I KO MDSCs in the presence of OVA peptide, Treg expansion was not significantly decreased (77.0 :!: 10.0%; p < 0.001). Taken together, these data suggest that MDSC-mediated Treg expansion is Ag-specific and MHC class II dependent.
We next asked whether MDSC-mediated suppression of naive CD4+CD25-OT-11 TCR transgenic T cell proliferation was Agand/or MHC-restricted. Using the same experimental design described in Fig. l , we found that suppression of CD4+CD25-T cell proliferation was both Ag and MHC class II dependent. We again performed FACS analysis for CFSE-labeled cells ( Fig. 2A) in four separate and reproducible experiments and found a significant proportion of CD4+CD25-OT-11 T cells proliferated in the presence of OVA peptide and irradiated naive splenocytes (53.5 ± 5.4%) (CT. Fig. 28 ). In the presence of WT MDSCs and OVA peptide or actin-OVA MDSCs, the proliferation of CD4.CD25-0T-11 T cells was significantly suppressed (9.4 :!: 2.6% and 18. .., Collectively, these data indicate that both MDSC-mediated suppression of T cell proliferation and Treg expansion are Agdependent and MHC class 11-restricted processes.
MDSCs prevent the onset of auroreacrive T cell-mediated diabetes
Evaluation of autoimmune responses against natural autoantigens has been impeded due to the polyclonal nature of autoreactive T cells and the lack of traceable markers for in vivo studies. Moreover, the results depicted in Figs. I and 2 indicate that both MDSC-mediated suppression of T cell proliferation and Treg expansion were both Ag dependent and MHC class II restricted. Therefore, we chose a well-characterized TID model (18) in which a surrogate autoantigen and Ag-specific TCR transgenic T cells were used to induce diabetes. In this model, T cells isolated from the CD4-HA-TCR transgenic mice were adoptively transferred into INS-HNRAG_,_ mice. For the proof-of-principle study, we used MDSCs isolated from tumor-bearing mice and HA peptide as autoantigen to induce suppression of autoreactive T cells and expansion of autoreactive Tregs. Consistent with previous repons (18) , the onset of diabetes, as determined by high blood glucose levels (~200 mg/dl), was readily detectable 7-10 d after T cell injection. This was true for all treated mice that received MDSCs plus OVA. control cells from Fr.3 cells plus HA, or PBS. However, the incidence of disease was drastically decreased in mice receiving MDSCs plus HA peptides. with 75% of all treated mice remaining diabetes free ( Fig. 3; p < 0 MDSCs plus HA peptide can effectively suppress the HA-specific T cell-mediated immune response against pancreatic islet cells expressing HA and, thus, prevent the development of diabetes in INS-HNRAG_,_ recipient mice.
MDSCs inhibit lymphocyte infiltration and insuliris
Lymphocyte infiltration and the resultant inflammation is a hallmark feature of diabetes. To better understand the effect of MDSCs on the suppression of diabetes development, we examined the histological changes in the pancreata of treated mice. H&E staining The Journal of Immunology indicated those recipients of MDSCs plus HA peptide had intact islets, and the severity of insulit is in these mice was markedly reduced (Fig. 4, upper left panel) . In sharp conrra. t, examination of nontreated (PBS) mice showed massive peri-islet infiltration of mononuclear cells (Fig. 4, upper right panel) . These ohservations were further verified by assessing CD4 T lymphocyte infiltration. MDSC plus HA peptide recipients showed o nly minimal staining (Fig. 4, middle leji panel) , whereas the islets recovered fro m PBStreated mice contai ned large numbers of CD4 T cells (Fig. 4,  middle right panel) . Furthermore, immunohistochemical staining for insulin revealed strong insulin expression in the intact islets of mice treated with MDSCs pl us HA (Fig. 4, lower left panel) . On the contrary, insulin production was almost absent from the pancreata of mice that received transferred T cells and PBS (Fig. 4,  lower right panel) . These results indicate that transfer of MDSCs effectively inhibits the infiltration of T lymphocytes into is lets, thus avoiding the harmful inflammatory response against islet cells and destruction of insulin-producing ~ cells.
MDSCs mediate T cell tolerance
We postulated that the profound suppression ofT cell infiltration into the islets of treated mice likely resulted from potent induction of T cell to lerance by MDSCs. To test this idea, we rc isolatcd autoreactive CD4-HA-TC R T cells fro m treated mice and exam-. ined their abil ity to proliferate in vitro. As shown in although there was no substantial difference in fFN--y production between all HA-CD4 T cell transferred groups, large amounts of IL-l 0 and TGF-~ were detected only in samples from diabetesfree mice treated with MDSCs + HA ( Fig. 58 ; p < 0.00 I). This indicates that regulatory, rather than inflammatory, cytokines were generated in vivo in the presence of MDSCs, and, hence, these factors may play a critical role in the induction ofT cell tolerance by MDSCs.
MDSCs induce Treg developme111
Previous studies from our group and others have demonstrated that MDSCs exhibit an exceptional ability to activate and expand Tregs (6, 17) . a cell type shown to be a key component in the regulation ofT I D and other autoimmune responses. To assess the potential involvement of Tregs in the control of TID by MDSCs, Treg development in secondary lymphoid organs (i.e., spleen) was evaluated. As shown in Fig. 6A , T cells recovered from diabetesfree mice receiving MDSCs and HA peptide contained a significantly higher percentage (35.5%) of Foxp3TCD4TCD25T T cells compared with that of T cells recovered from diabetic mice ( 15.0%) receiving the same treatment or control treatments. We further confirmed these findings by examining Foxp3 gene expression by both RT-PCR (F ig. 68, upper panel) and real-time RT-PCR (Fig. 68, lower panel) , which demonstrated that the highest level of Foxp3 gene expression was detected in nondiabetic mice that received MDSC and HA treatment (lane 1). These results suggest that transfer of HA pe ptide pulsed MDSCs induced a considerable proportion of autoreactive T cells to become Tregs. MDSC SUPPRESSES TID ONSET mice recetvmg MDSC plus H A were cultured a lo ne or in the presence of HA peptide at various ratios . The results indicate that the CD25+ T cells from nondiabetic mice mediated potent suppression of Ag-specific T cell proliferation in a dose-dependent manner (Fig. 6C ).
E./ Jeers of MDSCs on rhe developmenr 1!{ diaberes in NODISCID mice
To test whether MDSCs could affect the developme nt of TID in another murine model, NOD/SC!D mice were adoptively transfen ed with PBS , splenic CD4+ T cells isolated from NOD diabetic mice. or splenic CD4+ T cell s from NOD d iabetic mice along with MDSCs. NOD/SC!D mice treated with PBS did not develop diabetes (nontreatment, Fig. 7A ). In sharp contrast. NOD/SCID mice, which received auto reactive CD4+ T cells from diabetic NOD mice, d id become diabetic around day 10, as evidenced by fasti ng blood g lu cose levels over 200 mg/dl (CD4, Fig. 7A ). However, a sing le adoptive transfer of MDSCs effectively decreased the rate of diabetes development (CD4 + MDSC. Fig. 7A ), and 60% of the animals remained diabetes-free as long as 100 d posttreatme nt. We also assessed the extent of le ukocyte infiltration, a hallmark of insulitis, in the above mice at 15 d postinjection. We consistently found that adoptive transfer of CD4+ T cell s. versus PBS control transfer, sig nificantly increased the extent of leukocyte infiltration into the pancreata of NOD/SCID mice (non treatment versus CD4, Fig. 7 B) . In contrast, inclusion of MDSCs re markably decreased the extent of leukocyte infiltration (Fig. 7 B) . These findings regarding dysregulated g lucose and insulitis suggest that MDSCs can suppress autoreactive T cells a nd thereby prevent TID in the NOD syste m. As shown in Supplemental Fasting blood glucose levels were monitored from days 0 to 100. Number of mice in each group is indicated in parcnrheses. In the diabetes incidence experiment of A, comparisons were made bcrwcen several groups, including nonrreatment versus CD4 T cell alone 
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The Journal of Immunology that in vitro MDSC-mediated suppression of CD4+CD25-T cell proliferation and Treg expansion were Ag-dependent, MHC class 11-restricted processes. and that MDSCs were effective at perturbing the autoimmune response in the two diabetic animal models tested. Using a transgenic murine model of autoimmune diabetes, we demonstrated that injection of CD 115+Gr-l + MDSCs and HA peptide, a surrogate autoantigen, could efficiently protect INS-HNRAG_,_ mice from HA-specific TCR T cell-mediated diabetes in an Ag-dependent fashion. In addition, we observed markedly reduced lymphocyte infiltration and insulitis in t11e islets of the MDSC-treated mice. We also confirmed the ability of MDSCs to prevent the natural autoimmune T cell response in NOD/SCID diabetic mice. These findings suggest that MDSCs may have great translational implications for treating TID and other autoimmune diseases. The protective effects afforded by MDSC treatment include hypoproliferation of autoreactive T cells and dramatically decreased infiltration ofT lymphocytes into pancreatic islets in the diabetes-free treated mice. The latter likely results from an early inhibition of HA-specific T cell expansion in secondary lymphoid organs, as well as specific target organs (pancreas). This inference is supponed by previous studies documenting a profound suppression of activated T cell proliferation by MDSC transfer in both tumor (6, 19) and allogeneic bone marrow transplantation models (13 ) . Given the fact that peri-islet infiltration occurs prior to ~ cell destruction, as observed in NOD mice and TCR-transgenic models (20) , the suppression of autoreactive T cell responses by transferred MDSCs may account for the suppression of the autoimmune response and prevention of Tl D onset.
Tregs are widely recognized as crucial players in the development of TID. Previous repons have shown that defects in the frequency and/or function of Tregs are closely associated with the onset or progression of TID in both NOD mice (21) (22) (23) and human patients with TID (24, 25) . Moreover, Treg-based therapies have been under extensive investigation. Two primary strategies for the therapeutic application of Tregs include in vivo induction (26, 27) and in vitro expansion (28, 29) . Compared with the currently available approaches, MDSCs, which can be efficiently derived from embryonic and hematopoietic stem cells in vitro (13) , may offer a unique opponunity for specific immune intervention in Tl D and other autoimmune diseases by inducing Ag-specific Tregs, which are able to suppress directly autoreactive T cells.
Most interestingly, using the NOD/SCID model, we have demonstrated that a one-time injection of MDSCs can provide long-term protection against tl1e onset ofT I D. We and others have shown that monocytic MDSCs may play a key role in preventing graft-versus-host disease in allo-organ transplantation ( 12, 13) . Using our Gr-I+CDIIb+ MDSC population, we observed a significant treatment effect even at doses as low as I X 10 7 /mouse and with only a diminutive monocytic population ( 4-6%; Supplemental Fig. 2) . We continue to investigate the relative potency of monocytic versus granulocytic MDSCs. Quantifying the relative abilities of monocytic and granulocytic MDSCs to provoke immune suppression and give rise to Ag-specific immune tolerance is an area of continued investigation.
In conclusion, our findings clearly indicate that transfer of MDSCs conferred an exceptional capability to establish immune tolerance to self-Ag and protect against the onset of autoimmune TID.
